tbuckley/cabot-search huggingface dataset:
Abstract 993: A high-throughput peptide array screen of H3K9 methyl effectors identifies UHRF1 as an exception to the “phospho/methyl switch.”
Authors: Scott B. Rothbart, Stephen M. Fuchs, Nataliya Nady, Krzysztof Krajewski, Wolfram Tempel, Sheng Xue, Aimee N. Iberg, Dalia Barsyte-Lovejoy, Jorge Y. Martinez, Mark T. Bedford, Cheryl H. Arrowsmith, Brian D. Strahl
Journal: Cancer Research (2012)

Abstract Increasing evidence suggests that histone post-translational modifications (PTMs) function in combination to regulate the diverse activities associated with chromatin. However, the mechanisms through which multiple histone PTMs influence the association of effector proteins with chromatin is poorly understood. To address this problem, we recently developed a histone peptide array platform containing singly- and multiply-modified histone peptides to examine the binding of chromatin-associated proteins. Using these arrays, we surveyed protein domains that bound methylated H3K9, and uncovered a number of PTM “patterns” that influenced the association with this mark. Interestingly, while most H3K9 methyl binders were ejected by neighboring H3S10 phosphorylation (a PTM enriched in G2/M-phase chromatin), the tandem Tudor domain (TTD) of UHRF1 was insensitive to this known “phospho/methyl switch”. In agreement, structural and biophysical studies confirmed the insensitivity of the UHRF1 TTD to H3S10 phosphorylation. Furthermore, we found that UHRF1 remains bound to chromatin throughout the cell cycle in contrast to HP1, which is ejected from chromatin during mitosis. These results suggest an important role for this ubiquitin ligase during mitosis. Significantly, we further find that the TTD of UHRF1 regulates global DNA methylation, thus definitively linking H3K9me3 binding by UHRF1 to the maintenance of DNA methylation. Taken together, our data suggest that the regulation of DNA methylation by UHRF1 extends beyond S-phase and requires H3K9me3 recognition during mitosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 993. doi:1538-7445.AM2012-993
Intrauterine growth retardation and umbilical artery flow.
Authors: L McKnight
Journal: BMJ (1990)

renew the plasticine lining and repeat the procedure until one is confident in the mechanics of the resectoscope.We have used this model regularly at our gynaecological endoscopy workshops and the response of trainees has been universally positive.With minor modifications, urologists in training and others who use a resectoscope within a cavity may also find it a useful aid for endoscopic procedures.
I-123 Hydroxyiodobenzyl Propanediamine (HIPDM) Cerebral Blood Flow Imaging Demonstrating Transtentorial Diaschisis
Authors: WEI-JEN SHIH, STEVEN T. DEKOSKY, JOHN J. COUPAL, GUY SIMMONS, CALIXTO PULMANO, HANK F. KUNG, U YUN RYO, DAVID B. CLARK
Journal: Clinical Nuclear Medicine (1990)

To assess the clinical significance of transtentorial diaschisis (TTD) as demonstrated by 1-123 HIPDM brain imaging, SPECT and/or planar images of 35 patients with stroke, 26 patients with Alzheimer's disease (AD), 2 patients with Creutzfeldt-Jakob disease (CJD), and 1 patient with a schizoaffective disorder were analyzed. TTD was observed in 21 of the 35 patients with strokes. In 13 stroke patients, TTD was associated with large infarcts in the middle cerebral artery (MCA) territory; in the remaining 8 stroke patients, TTD was associated with internal capsule and/or basal ganglia infarcts. TTD was not associated with small occipital or parietal infarcts. Despite cortical perfusion decrements, TTD was not seen in the AD patients, the CJD patients, or the patient with schizoaffective disorder. It is concluded that 1) TTD frequently occurs following cerebral infarct of the MCA territory (60% of the patients in this sample); 2) absence of TTD in the presence of a large cerebral perfusion abnormality may represent neuronal dysfunction of the cerebral cortex; and 3) the presence of TTD without a significant cortical perfusion abnormality may indicate basal ganglia and/or internal capsule infarct.
Evidence of an association between non-Hodgkin's lymphoma and skin cancer
Authors: J. Adami, M. Frisch, J. Yuen, B. Glimelius, M. Melbye
Journal: BMJ (1995)

<h3>Abstract</h3> <b>Objective</b>: To investigate a possible link between exposure to ultraviolet light and the almost epidemic increase in non-Hodgkin9s lymphoma worldwide. Because ultraviolet light is known to cause skin cancers, the association between non-Hodgkin9s lymphoma and skin cancer was studied. <b>Design</b>: Secondary occurrence of either malignant melanoma or squamous cell skin cancer in cohorts of patients with a first diagnosis of either non-Hodgkin9s lymphoma or chronic lymphocytic leukaemia, and vice versa, were studied. Expected numbers of subsequent cancers were calculated by sex, age, and period specific national incidence rates multiplied by the person years under observation in the cohorts. <b>Setting</b>: Denmark (1943-89) and Sweden (1958-89). <b>Subjects</b>: Four population based cohorts identified in the nationwide cancer registries (34641 people with non-Hodgkin9s lymphoma, 17400 with chronic lymphocytic leukaemia, 34989 with malignant melanoma, 25980 with squamous cell skin cancer). A total of 562085 person years were accrued for the analysis. <b>Main outcome measures</b>: The ratios of observed to expected cancers (the standardised incidence ratio) served as a measure of the relative risk. <b>Results</b>: The relative risk for developing squamous cell skin cancer was 5.5 (95% confidence interval 4.6 to 6.6) among patients with non-Hodgkin9s lymphoma and 8.6 (7.2 to 10.3) among patients with chronic lymphocytic leukaemia. The relative risks remained high over more than 15 years of follow up. Relative risks for malignant melanoma were 2.4 (1.8 to 3.2) for patients with non-Hodgkin9s lymphoma and 3.1 (2.1 to 4.4) for patients with chronic lymphocytic leukaemia. After squamous cell skin cancer had been diagnosed there was a twofold excess risk for non-Hodgkin9s lymphoma and chronic lymphocytic leukaemia. By contrast, in each of the cohorts the general cancer risks excluding skin and lymphoproliferative malignancies were close to the expected. <b>Conclusions</b>: The occurrence of non-Hodgkin9s lymphoma and skin cancer are strongly associated; this supports the hypothesis that the secular increase in exposure to ultraviolet light may have contributed to the increasing incidence of non-Hodgkin9s lymphoma in recent decades <h3>Key messages</h3> Key messages Ultraviolet light is known to be immunosuppressive and to have causal links to skin cancer Non-Hodgkin9s lymphoma is strongly associated with skin cancer Exposure to ultraviolet light may have contributed to the increasing incidence of non-Hodgkin9s lymphoma in recent decades
Medical Institutions of San Francisco.
Authors: L. C. Lane
Journal: JAMA (1894)

San Francisco, April 26, 1894. <h3>To the Editor:</h3> —The American Medical Associationwill meet in San Francisco June 5 to 8. During the meeting the members will be cordially invited to visit the following institutions: City and County Hospital, Potrero Avenue and 22d Street, contains 450 beds. Superintendent, F. H. Titus; visiting surgeons, R. A. McLean, C. N. Ellinwood and G. F. Shiels; visiting physicians, W. W. Kerr and J. O. Hirschfelder; oculists and aurists, W. E. Hopkins and Geo. Merritt; visiting gynecologists, H. Kreutzmann and C. A. von Hoffmann. St. Mary's Hospital, First and Bryant Streets, is conducted by the Sisters of Mercy. Visiting surgeon, A. T. Leonard; gynecologist, Luke Robinson; physicians, W. S. Thorne and M. J. Fottrell; oculists, G. H. Powers and W. E. Hopkins. German Hospital, 14th and Noe Streets, contains 200 beds. Visiting surgeon, J. F. Morse; ophthalmologist, A. Barkan; gynecologist, H. Kreutzmann; physician,
Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose
Authors: Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Susan F. Leitman, Paolo Anderlini, John P. Klein, Mary M. Horowitz, John P. Miller, Roberta J. King, Dennis L. Confer
Journal: Blood (2009)
α <sub>1</sub> -Adrenoceptor-Mediated Breakdown of Phosphatidylinositol 4,5-Bisphosphate Inhibits Pinacidil-Activated ATP-Sensitive K <sup>+</sup> Currents in Rat Ventricular Myocytes
Authors: Tetsuya Haruna, Hidetada Yoshida, Tomoe Y. Nakamura, Lai-Hua Xie, Hideo Otani, Tomonori Ninomiya, Makoto Takano, William A. Coetzee, Minoru Horie
Journal: Circulation Research (2002)

Phosphatidylinositol 4,5-bisphosphate (PIP 2 ) stimulates ATP-sensitive K + (K ATP ) channel activity. Because phospholipase C (PLC) hydrolyzes membrane-bound PIP 2 , which in turn may potentially decrease K ATP channel activity, we investigated the effects of the α 1 -adrenoceptor-G q -PLC signal transduction axis on pinacidil-activated K ATP channel activity in adult rat and neonatal mouse ventricular myocytes. The α 1 -adrenoceptor agonist methoxamine (MTX) reversibly inhibited the pinacidil-activated K ATP current in a concentration-dependent manner (IC 50 20.9±6.6 μmol/L). This inhibition did not occur when the specific α 1 -adrenoceptor antagonist, prazosin, was present. An involvement of G proteins is suggested by the ability of GDPβS to prevent this response. Blockade of PLC by U-73122 (2 μmol/L) or neomycin (2 mmol/L) attenuated the MTX-induced inhibition of K ATP channel activity. In contrast, the MTX response was unaffected by protein kinase C inhibition or stimulation by H-7 (100 μmol/L) or phorbol 12,13-didecanoate. The MTX-induced inhibition became irreversible in the presence of wortmannin (20 μmol/L), an inhibitor of phosphatidylinositol-4 kinase, which is expected to prevent membrane PIP 2 replenishment. In excised inside-out patch membranes, pinacidil induced a significantly rightward shift of ATP sensitivity of the channel. This phenomenon was reversed by pretreatment of myocytes with MTX. Direct visualization of PIP 2 subcellular distribution using a PLCδ pleckstrin homology domain-green fluorescent protein fusion constructs revealed reversible translocation of green fluorescent protein fluorescence from the membrane to the cytosol after α 1 -adrenoceptor stimulation. Our data demonstrate that α 1 -adrenoceptor stimulation reduces the membrane PIP 2 level, which in turn inhibits pinacidil-activated K ATP channels.
Relapsed Colon Cancer
Authors: Guido Carillio, Raffaele Longo
Journal: New England Journal of Medicine (2005)

A 67-year-old man presented with an asymptomatic swelling in the lateral surface of the left thigh three years after resection of a carcinoma of the left colon and synchronous liver metastasis (tumor–node–metastasis stage T3N2M1, according to International Union against Cancer staging) and subsequent chemotherapy. A computed tomographic (CT) scan showed an isodense formation beside the quadriceps muscle (Panel A, arrow). A positron-emission tomographic scan showed signal enhancement in the left thigh due to enhanced metabolic activity of this lesion (Panel B, arrow). The patient underwent surgical resection of the lesion, and histologic examination confirmed metastasis of the colon carcinoma. Two . . .
Identical mutations in unrelated families with generalized resistance to thyroid hormone occur in cytosine-guanine-rich areas of the thyroid hormone receptor beta gene. Analysis of 15 families.
Authors: R E Weiss, M Weinberg, S Refetoff
Journal: Journal of Clinical Investigation (1993)

Generalized resistance to thyroid hormone (GRTH) is a syndrome of variable reduction of tissue responsiveness to thyroid hormone. 28 different point mutations in the human thyroid hormone receptor beta (TR beta) gene have been associated with GRTH. These mutations are clustered in two regions of the T3 binding domain of the TR beta (codons 310-347 and 417-453). We now report point mutations in the TR beta gene of six additional families with GRTH and show that three mutations occurred each in three families with GRTH, and that three other mutations were each present in two families. In 11 of these 15 families, lack of a common ancestor could be confirmed by genetic analysis. 28 of the 38 point mutations so far identified, including all those occurring in more than one family, are located in cytosine-guanine-rich areas of the TR beta gene. Differences in clinical and laboratory findings in unrelated families harboring the same TR beta mutation suggest that genetic variability of other factors modulate the expression of thyroid hormone action.
ANALYSIS OF IN-STENT RESTENOSIS PATTERN BY OPTICAL COHERENCE TOMOGRAPHY: INPACT OF DIFFERENCE IN STENT TYPE AND FOLLOW-UP PERIOD
Authors: Ippei Kosedo, Shingo Hosogi, Yuki Tsujimoto, Kentaro Shibayama, Naoki Saito, Suguru Otsuru, Yoji Okamoto, Mana Kusunose, Masao Imai, Hiroshi Tasaka, Daiji Hasegawa, Yoshikazu Shigemoto, Seiji Habara, Hiroyuki Tanaka, Takeshi Maruo, Akitoshi Hirono, Yoshiharu Nishibori, Yasushi Fuku, Naoki Oka, Harumi Katoh, Hiroyuki Yamamoto, Satoki Fujii, Tsuyoshi Goto, Kazushige Kadota, Kazuaki Mitsudo
Journal: Journal of the American College of Cardiology (2010)
Coronary vascular characteristics of the segment with myocardial bridge: is it more constrictive in response to acetylcholine?
Authors: Hiroki Teragawa, Yukihiro Fukuda, Keiji Matsuda, Kentaro Ueda, Kenya Sakal, Sou Takenaka, Fumiharu Miura, Hidekazu Hirao, Togo Yamagata, Hideo Matsuura, Kazuaki Chayama
Journal: Journal of the American College of Cardiology (2002)
Need for open access non-screening mammography in a hospital with a specialist breast clinic service.
Authors: J. J. Curtin, M. A. Sampson
Journal: BMJ (1992)

OBJECTIVE--Assessment of open access non-screening mammography in a hospital with a breast clinic. DESIGN--Retrospective analysis of patients sent for first mammogram to our open access service by general practitioners and breast clinic in the year April 1989 to March 1990. SETTING--District general hospital serving 200,000 people before the introduction of breast screening. SUBJECTS--361 symptomatic women referred directly by general practitioners and 226 women referred by the breast clinic for first, non-screening mammograms. MAIN OUTCOME MEASURES--Radiographic reports on all patients. Final diagnosis in patients reported as having possible or probable neoplasm. RESULTS--Of the women referred directly by general practitioners one (0.2%) was reported as showing probable malignancy (later histologically confirmed) and 15 (4%) as showing possible malignancy (on follow up none had proved malignancy). Of the women referred by the breast clinic 38 (17%) were reported as showing probable malignancy (all had confirmed carcinomas) and 35 (15%) as showing possible malignancy (19 (54%) had proved malignancy). 18 of the proved malignancies were in women under 50 years old, 26 were in women over 64 years, and 14 were in women of screening age. 54 (93%) of the 58 patients with proved breast cancer and an abnormal mammogram had a discrete breast lump. CONCLUSIONS--General practitioners accurately divided women into low and high risk groups, resulting in few abnormalities being detected in patients referred directly for mammography. This suggests that an open access non-screening mammography service for general practitioners is unnecessary in an area with a specialist breast clinic. The large proportion of cancers in women outside of screening age emphasises the need for such clinics.
Abstract 1729: Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer
Authors: Jens P. Klussmann, Markus Stenner, Antje Weinell, Tobias Ponert, Aline Hardt, Moritz Hahn, Simon Preuss, Ernst J. Speel
Journal: Cancer Research (2010)

Abstract Background: The expression of the inhibitor of apoptosis protein survivin is shown to be a significant prognostic indicator in various human cancers. Its role in cancer of the major salivary glands remains unclear. Methods: We analysed the survivin expression in 171 patients with malignant parotid gland cancer (12 different histological subtypes) by means of immunohistochemistry. The experimental findings were correlated with clinicopathological and survival parameters. The mean follow-up time was 42 months. Results: There was no significant correlation of cytoplasmic survivin expression levels with the patients’ clinicopathological characteristics. A strong cytoplasmic expression of survivin was found in 25% of the examined tumors. High cytoplasmic survivin expression was an independent prognostic indicator for a significant poorer 5-year disease-free survival rate (31% versus 67%, p&amp;lt;0.0005) and overall survival (45% versus 62%, p=0.048). In the multivariate analysis survivn expression and distant metastasis were significant predictors for patient outcome (p=0.001, p&amp;lt;0.0005). Conclusions: The correlation between cytoplasmic survivin expression and survival probabilities of salivary gland malignancies might make this an effective tool in patient follow-up, prognosis and targeted therapy in future. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1729.
Set up "youth corps" to stave off future health problems, says public health champion
Authors: M. Limb
Journal: BMJ (2013)

The United Kingdom should revive a form of national service for young people to save them and the country from a burgeoning public health crisis, an expert has said.

John Ashton, the president of the UK Faculty of Public Health, said that a “youth corps” for 17 to 18 year olds would benefit society as a whole.

Young people would choose their activities, such as taking part in environmental or community development type projects or joining the army reserve, he said.

He added that without such a scheme many young people lacking jobs, education, and housing could experience long term health problems.

Ashton, who trained as a psychiatrist, said that the economic situation posed “serious” threats to …
Routine Preoperative Screening for HIV-Reply
Authors: Michael B. Hagen
Journal: JAMA (1988)

In Reply.—  The comments of our colleagues reflect the stress to which the growing HIV epidemic subjects our profession. They offer two main arguments for preoperative testing for HIV infection—to decrease risk to the physician and to provide better care for the patient. Let us consider them in turn.  A patient who needs our help but who can fatally infect us frightens everyone. Even before the appearance of HIV we faced risks: exposure to radiation, to bacterial or viral pathogens, and even occasionally to violent patients. When professional practice becomes a personal risk, we each must choose how much risk are we willing to accept. But to
Alternate-Day Prednisone Therapy
Authors: JOHN L. ABRUZZO
Journal: Annals of Internal Medicine (1975)

Editorial Notes1 May 1975Alternate-Day Prednisone TherapyJOHN L. ABRUZZO, M.D.JOHN L. ABRUZZO, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-82-5-714_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe paper by Dr. Hunder and colleagues in this issue, "Daily and Alternate-Day Corticosteroid Regimens in Treatment of Giant Cell Arteritis" (p. 613), reports a study that directly compared alternate-day prednisone therapy with a daily dose regimen, in randomly assigned groups. Their findings reaffirm the effectiveness of daily steroid therapy in giant cell arteritis, but the value of alternate-day prednisone therapy is less clear, and the results should not be extrapolated too far. The 90-mg dose of prednisone given once every other morning was clearly less effective than 15 mg given every 8 hours or 45 mg given once daily....References1. SOYKA L: Alternate-day corticosteroid therapy. Adv Pediatr 19:47-70, 1972 Google Scholar2. DLUHYLAULERTHORN RDG: Pharmacology and chemistry of adrenal corticosteroids. Med Clin North Am 57:1155-1165, 1973 CrossrefMedlineGoogle Scholar3. REICHLINGKLIGMAN GA: Alternate day corticosteroid. Arch Dermatol 89:980-983, 1961 CrossrefGoogle Scholar4. HARTERREDDYTHORN JWG: Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 269:591-596, 1963 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Medicine Thomas Jefferson University Philadelphia, Pennsylvania PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByGlucocorticoid TherapyGlucocorticoid TherapyRealistic guidelines of corticosteroid therapy in rheumatic diseaseComparison of Daily and Alternate-Day Prednisone During Chronic Maintenance Therapy: A Controlled Crossover StudyCorticotrophins and corticosteroidsSTEROID THERAPY: STILL A NEED FOR ANSWERS 1 May 1975Volume 82, Issue 5Page: 714-714KeywordsCorticosteroid therapyGiant cellsSteroid therapy Issue Published: 1 May 1975 PDF DownloadLoading ...
How Safe Can Cigarettes Be?
Authors: Alfred P. Fishman
Journal: New England Journal of Medicine (1979)

Everyone knows that cigarette smoking is bad for health, and most people are tired of being reminded about it. Nonetheless, the topic keeps on recurring because no one seems to know exactly what to do about it.The latest reminder of the evils of smoking is a report on Smoking and Health from the office of the Surgeon General.1 The volume is encyclopedic, and the statistics read like those of a plague or other major disaster. For example, about 350,000 people will die next year from disorders attributable to smoking. Many more will be seriously incapacitated. Specifics are provided about . . .
Postnatal Corticosteroids for Preterm Infants — Do What We Say, Not What We Do
Authors: Alan H. Jobe
Journal: New England Journal of Medicine (2004)

Physicians caring for pregnant women and their preterm infants have used corticosteroids since Liggins and Howie reported in 1972 that prenatal betamethasone decreased the incidence of the respiratory distress syndrome and increased the survival of preterm infants.1 This infatuation with corticosteroids is not unique to perinatal medicine; corticosteroids have been used for almost every human disease for which there is no effective therapy. Despite an astounding number of randomized, controlled trials of corticosteroids in perinatal medicine, we remain uncertain about their appropriate use. The Cochrane Review of 18 trials of prenatal corticosteroids demonstrated compelling benefits for infants delivered before 32 . . .
Recent Advances in Clinical and Experimental Transplantation
Authors: Felix T. Rapaport
Journal: JAMA (1977)

THE SIXTH International Congress of the Transplantation Society was characterized by a recrudescence of interest in the various aspects of transplantation biology and medicine, and particularly in cell-to-cell interaction. The general consensus at the close of the meeting was that a firm basis had been established for the acquisition of new biological facts of direct relevance, not only to transplantation, but also in the understanding of a wide variety of disease processes in man. <h3>CLINICAL AND EXPERIMENTAL ORGAN TRANSPLANTATION</h3> The 13th (and final) report of the International Human Renal Transplant Registry of The American College of Surgeons, National Institutes of Health, was one of the highlights of the Congress. This report detailed the experience with 24,193 kidney transplants performed at 301 institutions, including 165 in the United States, since 1963. Six institutions performed more than 51 transplants per year in each of the five years ending in June 1976; eight